Breaking News

Financial Report: BASi

October 18, 2013

Returns to profitability in the quarter

3Q Revenues:
$5.6 million (-22%)

3Q Earnings: $576,000 (loss of $246,000 3Q12)

YTD Revenues: $16.6 million (-24%)

YTD Earnings: $521,000 (loss of $3.6 million YTD13)

Comments: Service revenue for the quarter was down 20% to $4.2 million, impacted by the consolidation of BASi's Oregon lab into its West Lafayette facility. Product revenue decreased 27% to $1.4 million, primarily due to lower sales of Culex automated sampling systems. Earnings in the quarter are attributed to a higher gross margin and lower operating expenses. Restructuring charges impacted 2012 earnings.
blog comments powered by Disqus
  • Flexible Manufacturing Strategies

    Kristin Brooks, Contract Pharma||April 4, 2016
    Michael Lehmann of Patheon discusses solutions for pharmaceutical forecasting errors

  • Platinum Press Facility Tour

    Platinum Press Facility Tour

    Kristin Brooks, Contract Pharma||March 23, 2016
    Opens doors to new, 47,000-sq.-ft. packaging facility in Oakland, NJ

  • Biopharma Packaging Equipment Close-up

    Biopharma Packaging Equipment Close-up

    Kristin Brooks, Contract Pharma||March 7, 2016
    Sieghard Schuchmann of OPTIMA discusses biopharma trends impacting packaging equipment, and the latest capabilities

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.

  • Four Pillars to Guide Your CRO Search

    Four Pillars to Guide Your CRO Search

    Alan Findlater , WIL Research||November 17, 2015
    Tips on how to seek out the best possible CRO-Sponsor relationship

  • Getting Real

    Michael Pollock, PPD||November 17, 2015
    Partnering for clinical and real-world evidence studies